The role of sterile chitosan-based dressing in reducing complications related to a peripherally inserted central catheter in patients with hematological tumors

Wanyun Huang, Jiandi Xu

Department of Hematology, Maoming People's Hospital, Maoming, China

Contributions: (I) Conception and design: W Huang; (II) Administrative support: W Huang; (III) Provision of study materials or patients: W Huang; (IV) Collection and assembly of data: J Xu; (V) Data analysis and interpretation: W Huang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Wanyun Huang. Department of Hematology, Maoming People's Hospital, Maoming 525000, China. Email: hwy3238@163.com.

Background: Intravenous chemotherapy is one of the most common treatments for hematological tumors, a major threat to human health and life. Due to its safety, comfort, and convenience, a peripherally inserted central catheter (PICC) is the preferred route of administration of intravenous chemotherapy. However, some PICC-related complications are drawing increasing attention. In this study, we investigated the use and role of sterile chitosan-based dressing in PICC-related complications in patients with hematological tumors.

Methods: We retrospectively analyzed the clinical data of 205 patients with hematological tumors who had a PICC placed. The patients were divided into two groups, the observation group (sterile chitosan-based dressing, n=105) and the control group (sterile gauze dressing; n=100). The incidences of bleeding, infection, poor healing, and phlebitis, as well as the risk of bleeding, infection, and poor healing at the puncture site within a week of PICC placement, were analyzed.

Results: The overall incidences of bleeding, infection, and poor healing were, respectively, 42.9%, 6.7%, and 6.7% in the observation group and 63.0%, 22.0%, and 34% in the control group (all P<0.05). The risk of local bleeding was significantly lower in the observation group than in the control group [odds ratio (OR) 0.366; 95% confidence interval (CI): 0.211–0.634; P<0.001]. The risk of infection (OR 0.214; 95% CI: 0.088–0.522; P<0.001) and the risk of poor healing (OR 0.139; 95% CI: 0.058–0.331; P<0.001) were significantly lower in the observation group than in the control group.

Conclusions: For patients with hematological tumors, sterile chitosan-based dressing after PICC placement reduces the risk of bleeding and infection and promotes healing at the puncture site.

Keywords: Sterile chitosan-based dressing; peripherally inserted central catheter (PICC); catheterization complications; hematological tumors

doi: 10.21037/apm-20-1235
View this article at: http://dx.doi.org/10.21037/apm-20-1235

Introduction

Hematological tumors are malignant tumors originating from the hematopoietic system, among which leukemia, lymphoma, and multiple myeloma are the most common. As a special kind of tumor, the prevalence rate of hematological tumors is increasing year by year. Traditional treatment methods such as radiotherapy and chemotherapy play an important role in the fight against...
tumor cells, but their toxic and side effects are great and they will kill normal cells at the same time. In 2018, James and Honjo won the Nobel Prize in Physiology or Medicine for cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death receptor 1 (PD-1), respectively (1). Immune Checkpoint Blocker (ICB) controls and clears tumors by blocking abnormally activated immunosuppressive pathways, reactivating T cell immune efficacy, restoring and enhancing systemic anti-tumor immune responses, have achieved positive efficacy in many solid tumors and hematological tumors. In 2015, PD-1 inhibitor Nivolumab cured relapse/refractory classical Hodgkin’s lymphoma (R/RcHL), resulting in overall response rate of 87% (2), which has inspired the researchers to wonder whether ICB would have gained good anticancer effect as a potential novel treatment. Many PD-1 and CTLA-4 blockers have been developed and put into clinical use as single drugs or combined treatment. The initial results are good and have become a new choice for patients with hematological tumors.

Hematological tumors require a long treatment time, and intravenous chemotherapy is one of the common treatments. However, peripheral intravenous chemotherapy is prone to drug leakage, vascular sclerosis, increased vascular fragility, vascular stenosis, and reduced vascular elasticity, making it difficult or impossible to infuse any solution (3). A peripherally inserted central catheter (PICC) can address this problem. During the procedure, a catheter is inserted via a peripheral access (basilic vein, median cubital vein, cephalic vein) and advanced into the superior vena cava. PICC placement is widely used for chemotherapy in patients with hematological tumors. However, PICC sheaths cause greater vascular damage due to their large size, which, along with weakened immunity and coagulation disorders in patients with hematological tumors, increases the risks of bleeding, infection, phlebitis, and poor healing at the puncture point after PICC placement. This affects treatment, prolongs hospitalization, and increases medical expenses if not treated properly (4). Chitosan is a naturally occurring biocompatible polysaccharide that can activate the coagulation pathway and form an isolation layer to protect the wound. It reduces and stops bleeding, prevents infection, and promotes wound healing and is thus widely used to dress wounds after surgery (5). Seethamsetty found that Chitosan dressing is a competent hemostatic agent that significantly reduced the post-extraction bleeding, with better pain control and lower incidence of wound infection (6). To date, no studies have investigated its role after PICC placement. In this study, we analyzed the clinical data of patients with sterile chitosan-based dressing after PICC placement between April 2018 and March 2020 and found that sterile chitosan-based dressing significantly reduced PICC-related complications. Interestingly, the situation of extravasation within 24 hours, infection, and healing were used as dependent variables to conduct ordered multi-classification logistic regression analysis, and multiple variables were found to be correlated with these factors. The results are reported below. We present the following article in accordance with the STROBE reporting checklist (available at http://dx.doi.org/10.21037/apm-20-1235).

Methods

General information

We retrospectively analyzed the clinical data of 216 patients with hematological tumors who received treatment via a PICC at the Department of Hematology, Maoming People’s Hospital, between April 2018 and March 2020. Among them, 205 patients met the entry criteria and were included in this study. Inclusion criteria were as follows: (I) patients who were eligible for PICC placement; (II) patients who were conscious and had the ability to cooperate with PICC placement; and (III) patients who received catheter maintenance or follow-up by a trained nurse for at least a week after PICC placement. Exclusion criteria were as follows: (I) critically ill patients who were unconscious or unable to cooperate; and (II) patients with persistent bleeding at the puncture site during or after PICC placement. The patients were divided into two groups, the control group (sterile gauze dressing; n=100) and the observation group (sterile chitosan-based dressing; n=105). This study was approved by the Medical Ethics Committee of Maoming People’s Hospital (ID: PJKY2020 MI-001-01). All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was taken from all the patients.

Procedure

A 4-Fr single-lumen catheter with a three-way valve (C. R. Bard, Inc., USA) was inserted with the modified Seldinger technique under the guidance of ultrasound B and maintained by a trained PICC specialist nurse of our department. In the control group, common gauze dressing
was used to compress and secure the PICC: 2.5 cm × 1.5 cm 24-layer gauze (made from 10 cm × 10 cm nonwoven fabric) was used to compress the puncture site, which was then covered with 12 cm × 15 cm self-adhesive film dressing (SOFT 3000) and another layer of 2.5 cm × 1.5 cm 24-layer gauze (made from 10 cm × 10 cm nonwoven fabric) and secured with 1 cm × 8 cm elastic tape. In the observation group, 6 cm × 7 cm sterile chitosan-based dressing (Figure 1) was used to cover the puncture site, which was then covered with 2.5 cm × 1.5 cm 24-layer gauze (made from 10 cm × 10 cm nonwoven fabric), 12 cm × 15 cm self-adhesive film dressing (SOFT 3000), and another layer of 2.5 cm × 1.5 cm 24-layer gauze (made from 10 cm × 10 cm nonwoven fabric), and secured with 1 cm × 8 cm elastic tape. In both groups, the patients were instructed to press the puncture site with their thumb for at least 30 minutes. Accurate platelet counts are done by SK8800 Automatic blood cell analyzer using an electronic particle counting method. Accurate platelet counts are done by SK8800 Automatic blood cell analyzer using an electronic particle counting method. The patients received PICC-related health education once tip position was confirmed by X-ray. Moreover, the patients were instructed to minimize limb movement on the puncture side, not raise their arms for 24 hours, minimize strenuous limb movement on the puncture side for 3 days, and not lift any heavy object while the PICC was in place.

**Evaluation methods**

A trained attending nurse changed the dressings for PICCs. Bleeding at the puncture site was recorded during the first dressing change, and infection and healing at the puncture site were recorded at 1 week. During the first dressing change, bleeding at the puncture site was rated as “0” if there was no blood or minimal dark blood that did not exceed one-quarter of the area of the gauze or penetrate layer 2 of the lower layer of the sterile gauze, “1” if dark blood covered one-quarter to three-quarters of the area of the gauze or penetrated layer 2 or 3, “2” if dark blood covered the entire gauze or penetrated layer 4, and “3” if fresh blood was discovered on the gauze or bleeding was observed at the puncture site (7). For infection at the puncture site, no abnormal sign at the puncture site indicated no infection, redness and swelling indicated mild infection, firmness indicated moderate infection, and the presence of pus indicated severe infection (8). For puncture site healing, adherence of skin to the catheter (the catheter could not easily move) at the puncture site indicated good healing, and no adherence of skin to the catheter (easy catheter movement) indicated poor healing (4). Phlebitis was evaluated according to the *Infusion Therapy Standards of Practice* from the Infusion Nurses Society [2006]: 0: no symptoms; I: redness at the infusion site with or without pain: II: pain at the infusion site with redness and/or swelling; III: pain at the infusion site with redness and/or swelling and palpable cord-like veins; IV: pain at the infusion site with redness and/or swelling, palpable cord-like veins (>2.5 cm or 1 inch), and pus (9).

**Statistical analysis**

SPSS v20.0 was used for data analysis. Normally distributed measurement data are expressed as mean ± standard deviation and were analyzed with the independent-sample t-test. Count data are expressed as frequency (percentage) and were analyzed with the chi-squared test. Multivariate analysis was performed with logistic regression. P<0.05 was
considered statistically significant.

**Results**

**Overall medical complications**

Table 1 shows the general information of the patients, and Table 2 shows the details of PICC placement. Table 3 shows the incidences of PICC-related complications. The overall incidences of bleeding, infection, and poor healing were, respectively, 42.9%, 6.7%, and 6.7% in the observation group and 63.0%, 22.0%, and 34% in the control group (all P<0.05). Among the 205 patients, the overall incidences of catheter displacement, phlebitis, and thrombosis were 3.9%, 2.4%, and 2.4%, respectively, with no significant between-group difference.

**Multivariable analyses of the incidence of local bleeding**

The patients were divided into three grades by platelet count (<50×10⁹/L, 50×10⁹–100×10⁹/L, >100×10⁹/L). Pearson’s correlation coefficient was calculated to analyze the correlations between the dependent variable, bleeding within 24 hours of PICC placement, and the independent variables, which were sterile chitosan-based dressing, sex, age, body mass index (BMI), primary disease, hypertension, diabetes mellitus, initial placement, number of puncture attempts, incision methods, smooth placement, placement site, venous access, tip position, catheter displacement, PLT, PT, TT, APTT, and INR to identify significant variables at P<0.1. Sterile chitosan-based dressing was the only variable that was incorporated into the logistic regression equation. The results showed that the risk of infection and the risk of poor healing in the sterile chitosan-based dressing group were, respectively, 0.214 times and 0.139 times those in the common dressing group (both P<0.05). See Figure 3.

**Discussion**

Reliable venous access is essential for infusion therapy, especially in patients with hematological tumors. Intravenous infusion and catheter maintenance are important parts of nursing care. Infusion therapy is often administered via a peripheral catheter, but the catheter must be replaced regularly to prevent catheter-related complications, such as bleeding, phlebitis, and thrombophlebitis. A central catheter provides reliable venous access without repeated venipuncture, but it may cause life-threatening complications, such as pneumothorax, hemothorax, and bleeding (10).

Since the 1980s, PICC has been widely used to establish smooth vascular access. In addition to playing a key role in the treatment of patients with critical and potential life-threatening conditions, it has become an important tool for the treatment of patients with hematological tumors and provides the central venous access for long-term administration of antibiotics and chemotherapy drugs. It is easy and convenient to insert, causes few complications, provides reliable venous access, and has high patient satisfaction (11,12). Nevertheless, PICC-related complications have been reported, such as catheter-related bloodstream infection (CRBSI), deep vein thrombosis, and bleeding at the puncture site.

After PICC placement, bleeding at the puncture site is common in patients with hematological tumors. Some patients have low platelet count, a risk factor for bleeding at the puncture site. Bleeding may also occur in patients with a low level of coagulation factors. Some studies have shown that cancer-related thrombocytopenia increases the risk of bleeding, with a negative correlation between bleeding rate and platelet count, especially in patients with
### Table 1 General information

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Sex</th>
<th>Age</th>
<th>BMI</th>
<th>Primary disease</th>
<th>Comorbidities</th>
<th>WBC</th>
<th>PLT</th>
<th>Coagulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>100</td>
<td>M</td>
<td>43.11±15.10</td>
<td>22.41±3.28</td>
<td>AML</td>
<td>HTN</td>
<td>2.24±0.48</td>
<td>74.40±44.83</td>
<td>12.32±1.76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F</td>
<td>49</td>
<td>28</td>
<td>8</td>
<td>DM</td>
<td>17.39±1.44</td>
<td>71.83±40.96</td>
<td>17.36±1.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8</td>
<td>8</td>
<td>3</td>
<td>INR</td>
<td>29.02±5.68</td>
<td>29.09±5.82</td>
<td>29.02±5.68</td>
</tr>
<tr>
<td>Observation group</td>
<td>105</td>
<td>M</td>
<td>47.35±18.03</td>
<td>22.06±3.74</td>
<td>ALL</td>
<td>HTN</td>
<td>2.29±0.42</td>
<td>71.83±40.96</td>
<td>12.50±4.06</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F</td>
<td>48</td>
<td>8</td>
<td>23</td>
<td>DM</td>
<td>17.39±1.69</td>
<td>71.83±40.96</td>
<td>17.36±1.69</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>8</td>
<td>8</td>
<td>7</td>
<td>INR</td>
<td>29.02±5.68</td>
<td>29.09±5.82</td>
<td>29.02±5.68</td>
</tr>
<tr>
<td>Chi-squared</td>
<td>0.222</td>
<td>0.638</td>
<td>0.069</td>
<td>0.474</td>
<td>0.596</td>
<td>0.919</td>
<td>0.229</td>
<td>0.439</td>
<td>0.668</td>
</tr>
<tr>
<td>P</td>
<td>0.638</td>
<td>0.069</td>
<td>0.474</td>
<td>0.596</td>
<td>0.919</td>
<td>0.229</td>
<td>0.439</td>
<td>0.668</td>
<td>0.67</td>
</tr>
</tbody>
</table>

BMI, body mass index; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MM, multiple myeloma; NHL, non-Hodgkin's lymphoma; HTN, hypertension; DM, diabetes mellitus; PLT, platelets; PT, prothrombin time; TT, thrombin time; APTT, activated partial thromboplastin time; INR, international normalized ratio.

### Table 2 PICC placement

<table>
<thead>
<tr>
<th>Group</th>
<th>Yes</th>
<th>No</th>
<th>Yes</th>
<th>No</th>
<th>1</th>
<th>2</th>
<th>Transverse</th>
<th>Oblique</th>
<th>Left</th>
<th>Right</th>
<th>Basilic vein</th>
<th>Brachial vein</th>
<th>Median cubital vein</th>
<th>Cephalic vein</th>
<th>Tip position</th>
<th>Blood loss (pieces of gauze)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control group</td>
<td>91</td>
<td>9</td>
<td>82</td>
<td>18</td>
<td>89</td>
<td>11</td>
<td>55</td>
<td>45</td>
<td>73</td>
<td>27</td>
<td>73</td>
<td>11</td>
<td>7</td>
<td>9</td>
<td>5</td>
<td>32 39 24 82 11 7</td>
</tr>
<tr>
<td>Observation group</td>
<td>96</td>
<td>9</td>
<td>85</td>
<td>20</td>
<td>92</td>
<td>13</td>
<td>56</td>
<td>49</td>
<td>68</td>
<td>37</td>
<td>96</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>5</td>
<td>38 46 16 83 13 9</td>
</tr>
<tr>
<td>Chi-squared</td>
<td>0.012</td>
<td>0.914</td>
<td>0.037</td>
<td>0.847</td>
<td>0.094</td>
<td>0.759</td>
<td>0.067</td>
<td>0.811</td>
<td>0.203</td>
<td>0.005</td>
<td>2.57</td>
<td>0.301</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>0.914</td>
<td>0.037</td>
<td>0.094</td>
<td>0.759</td>
<td>0.067</td>
<td>0.811</td>
<td>0.203</td>
<td>0.005</td>
<td>2.57</td>
<td>0.301</td>
<td>0.914</td>
<td>0.037</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PICC, peripherally inserted central catheter.

### Table 3 PICC-related complications

<table>
<thead>
<tr>
<th>Complication</th>
<th>Bleeding</th>
<th>Local bleeding</th>
<th>Infection</th>
<th>Phlebitis</th>
<th>Thrombosis</th>
<th>Healing</th>
<th>Catheter displacement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
<td>Grade 0</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>None</td>
</tr>
<tr>
<td>Control group</td>
<td>63</td>
<td>37</td>
<td>34</td>
<td>43</td>
<td>16</td>
<td>7 (7.0%)</td>
<td>8 (8.0%)</td>
</tr>
<tr>
<td></td>
<td>(83.0%)</td>
<td>(37.0%)</td>
<td>(34.0%)</td>
<td>(43.0%)</td>
<td>(16.0%)</td>
<td>(7.0%)</td>
<td>(8.0%)</td>
</tr>
<tr>
<td>Observation group</td>
<td>45</td>
<td>60</td>
<td>63</td>
<td>30</td>
<td>9</td>
<td>8 (8.6%)</td>
<td>3 (2.9%)</td>
</tr>
<tr>
<td></td>
<td>(42.9%)</td>
<td>(57.1%)</td>
<td>(60.0%)</td>
<td>(28.6%)</td>
<td>(9.6%)</td>
<td>(8.6%)</td>
<td>(2.9%)</td>
</tr>
<tr>
<td>Chi-squared</td>
<td>8.337</td>
<td>13.794</td>
<td>10.43</td>
<td>6.609</td>
<td>0.258</td>
<td>23.917</td>
<td>8.741</td>
</tr>
<tr>
<td>P</td>
<td>0.004</td>
<td>0.003</td>
<td>0.015</td>
<td>0.085</td>
<td>0.611</td>
<td>0.003</td>
<td>0.003</td>
</tr>
</tbody>
</table>
hematological malignancies (13). Moreover, for patients with hematological tumors, thrombocytopenia significantly increases the risk of bleeding, especially when platelets are \(<50\times10^9/L\), as increased capillary fragility increases the bleeding rate (14,15). This study showed similar results: the risk of bleeding in the platelets \(<50\times10^9/L\) group was 3.068 times that in the platelets \(>100\times10^9/L\) group. In addition, chemotherapy drugs may irritate and damage the vascular mucosa, resulting in increased vascular permeability and bleeding at the puncture site. To address this problem, Wan et al. used alginate dressing that released natural celluloses, polysaccharides, and carbohydrates to promote wound healing. Upon contact with the wound exudate, the alginate dressing released calcium ions to accelerate clotting, thereby effectively reducing bleeding at the PICC puncture site (16). In this study, we used sterile chitosan-based dressing or sterile gauze to cover the PICC puncture site and found that sterile chitosan-based dressing had a superior hemostatic effect (local bleeding, \(P<0.05\)). In addition, the risk of local bleeding in the sterile chitosan-based dressing group was 0.366 times that in the common dressing group (Figure 1), which was consistent with the findings of Seethamsetty et al. (6). Chitosan is composed of N-acetylglucosamine and glucosamine. It is widely used in the medical field because of its superior biological properties, such as cell compatibility and anti-pyrogenic activity. Chitosan is a naturally occurring biocompatible polysaccharide that can activate the coagulation pathway to promote hemostasis. Due to its positive charge, chitosan attracts negatively charged red blood cells and platelets to form a sealed isolation film at the wound, which is further enhanced as more platelets and red blood cells accumulate at the wound to promote hemostasis and wound healing (17).

CRBSI is closely related to immunity. In patients with hematological tumors, PICC placement significantly increases the risk of (severe) infection due to neutropenia. Some studies have shown that infection was the most common and severe complication of PICC, with 1.5 to 6.6 infections per 100 catheter days. Bertoglio et al. conducted a prospective study and found that the incidence of CRBSI was 4.0% per catheter day (18). Fairhall showed that the incidence of PICC-related CRBSI was 4.3% per catheter day (19). Chitosan has unique antimicrobial activity and non-antigenicity, and its antimicrobial activity has been extensively studied. Conventional dressings often encapsulate antimicrobial agents, which are gradually released to achieve antimicrobial effects. In contrast, chitosan-based dressings have intrinsic, sustained antimicrobial activity against a wide range of microbial strains and are less toxic to tissues and cells (17,20). Similarly, this study showed that the incidence of infection was significantly lower in the sterile chitosan-based dressing group than in the common sterile dressing group (OR 0.214; Figure 2).

Sterile chitosan-based dressing was also superior to the common sterile dressing in promoting wound healing, (93.33% vs. 66%, \(P<0.05\)). Chitosan attracts inflammatory cells to the wound via its chemotactic effect, activates macrophages to synthesize and secrete interleukin 8, stimulates neovascularization and accelerates granulation tissue formation at the wound, and reduces the high level of
carbonic acid to indirectly improves the oxygen level at the wound, thereby promoting wound healing and repair (21).

Phlebitis is another common PICC-related complication. Its main causes include intimal damage due to repeated catheter movement in the vessel during or after placement and a local inflammatory response due to drug irritation and subsequent release of inflammatory mediators (22). The incidence of phlebitis is approximately 1.2% to 54.5% (23). In this study, the incidence of phlebitis was only 2.4%, which was attributable to careful operation by our nurses, proper securing and maintenance of the PICC, and patient education. Unclean dressing and postoperative infection are also risk factors for phlebitis (24). In this study, the incidence of infection was significantly lower in the observation group than in the control group, but no significant between-group difference was observed in the incidence of phlebitis, which may be related to the small sample size.

Conclusions

For patients with hematological tumors, sterile chitosan-based dressing effectively reduces the incidence of PICC-related adverse events such as bleeding and infection and promotes wound healing. This is a small study, and larger studies are needed to validate its results.

Acknowledgments

Funding: This work was supported by the High-level Hospital Construction Research Project of Maoming People’s Hospital [Reference No. Yueweihan (2018) 413].

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at http://dx.doi.org/10.21037/apm-20-1235

Data Sharing Statement: Available at http://dx.doi.org/10.21037/apm-20-1235

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apm-20-1235). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the Medical Ethics Committee of Maoming People’s Hospital (ID: PJKY2020 M1-001-01). All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was taken from all the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

7. Min C, Jie Z, Ying L, et al. Study on first dressing change time after PICC placement among patients with...